Subcutaneous peginterferon β-1a injection-site reaction experience and mitigation: Delphi analysis of the ALLOW study

Authors

Barry Hendin, Phoenix Neurological Associates
DeRen Huang, Neurology & Neuroscience Associates
Sibyl Wray, Hope Neurology
Robert T Naismith, Washington University School of Medicine in St. Louis
Sheri Rosenblatt, fit2market
Javier Zambrano, Biogen
Brian Werneburg, Biogen

Journal

Neurodegenerative Disease Management

Publication Date

2-1-2017

Volume

7

Issue

1

First Page

39

Last Page

47

Document Type

Open Access Publication

DOI

10.2217/nmt-2016-0032

Rights and Permissions

Hendin B, Huang D, Wray S, Naismith RT, Rosenblatt S, Zambrano J, Werneburg B. Subcutaneous peginterferon β-1a injection-site reaction experience and mitigation: Delphi analysis of the ALLOW study. Neurodegener Dis Manag. 2017 Feb;7(1):39-47. doi: 10.2217/nmt-2016-0032. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. For full bibliographic citation, please refer to the version available at www.futuremedicine.com.

Recommended Citation

Hendin, Barry; Huang, DeRen; Wray, Sibyl; Naismith, Robert T; Rosenblatt, Sheri; Zambrano, Javier; and Werneburg, Brian, "Subcutaneous peginterferon β-1a injection-site reaction experience and mitigation: Delphi analysis of the ALLOW study." Neurodegenerative Disease Management. 7, 1. 39 - 47. (2017).
https://digitalcommons.wustl.edu/oa_3/24